TX-GRC
20.10.2020 08:02:10 CEST | Business Wire | Press release
GRC (Green Revolution Cooling), the single-phase immersion-cooling authority® for data centres , today announces a new partnership contract with Total Data Centre Solutions (TDCS), a leading provider of mission critical and innovative infrastructure solutions for Data Centres throughout Europe and the Nordic region focused on carbon reduction and energy efficiency.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201019005928/en/
Through the partnership, TDCS will act as the agent for GRC in Europe, selling GRC’s ICEraQ® Micro-Modular, Rack-Based Immersion-Cooling Systems and ICEtank® Modular, Containerised data centres to clients primarily in the UK, the Nordic region, Germany and Luxembourg. Additionally, this new partnership now enables GRC to engage and support European data centre customers with a local European presence.
“GRC is delighted to partner with TDCS,” said Jim Weynand, Chief Revenue Officer, GRC. “The proliferation of AI, 5G, Edge computing, reduced carbon emissions, and more throughout Europe present new challenges for both legacy and new data centre builds. Our partnership with TDCS will ensure clients throughout Europe can seamlessly integrate immersion cooling into their existing infrastructures.”
After thoroughly assessing various immersion cooling solutions on the market, TDCS recognized that GRC’s immersion-cooling technology is a differentiator that brings value to their existing and potential clients. European clients can now acquire GRC’s immersion-cooling systems through TDCS in order to reduce energy use or power consumption, solve power and space density challenges, cut energy cooling costs significantly and place HPC compute close to where it’s needed and secure other benefits of GRC’s game-changing immersion-cooling solutions. Being the longest established immersion cooling company, with 11+ years’ experience and many blue-chip clients including The US Government, the US Air Force, and approved by most global server manufacturers – take out the fan and reap all the awards.
“It’s exciting to build this new partnership with GRC,” said Jonathan Evans, Founder of TDCS. “Joining GRC as an agent partner is an opportunity for us to offer clients best-of-breed single-phase liquid immersion cooling technology. We are passionate about reducing the carbon footprint and the OpEx of each, of our clients. The partnership of GRC and TDCS helps solve carbon and cost issues facing all data center owners and operators, which perfectly complements our sustainability portfolio of offerings from technologies to data centres."
About GRC
GRC is the immersion cooling authority® . The company's patented immersion-cooling technology radically simplifies deployment of data centre cooling infrastructure. By eliminating the need for chillers, CRACs, air handlers, humidity controls and other conventional cooling components, enterprises reduce their data centre design, build, energy, and maintenance costs. GRC’s solutions are deployed in seventeen countries and are ideal for next-gen applications platforms, including artificial intelligence, blockchain, HPC, 5G, and other Edge Computing and core applications. Their systems are environmentally resilient, sustainable, and space saving, making it possible to deploy the solution in virtually any location with minimal lead time. Visit http://grcooling.com for more information.
About Total Datacentre Solutions
TDCS is an End to End Data Centre Consultancy, founded in 2002. Specialising in reducing a client’s IT carbon footprint and CapEx/OpEx with new technologies. TDCS comprises a team of data centre business professionals, many with 30+ years of industry experience. Our aim is to provide clients with innovative technologies to help reduce their carbon footprints and optimize their CapEx/OpEx. Visit https://www.totaldatacentresolutions.co.uk for more information
View source version on businesswire.com: https://www.businesswire.com/news/home/20201019005928/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom